The Future of Wound Care Is Synthetic: Mirragen’s Breakthrough for Hard-to-Heal Wounds
Summary: In this episode of The Frank & Lizzie Show, hosts Frank Aviles and Lizzie Hutton interview AJ Ford (CEO, ETS) and Dr. Marc Gitterle on Mirragen, a borate-based bioactive glass fiber matrix (BBGFM). The discussion centers on Mirragen’s second RCT for diabetic foot ulcers (DFUs), showing 48% closure at 12 weeks vs 24% SOC (mITT, n=133) and 73% vs 42% per-protocol. Mirragen provides a synthetic scaffold for cellular infiltration, angiogenesis, and infection inhibition, outperforming tissue-based products in cost, versatility, and real-world efficacy. Case studies demonstrate limb salvage in tendon-exposed and osteomyelitis-complicated DFUs.
Key Highlights:
- RCT Results: 48% healed (Mirragen) vs 24% SOC (mITT); 73% vs 42% per-protocol (p<0.05).
- Mechanism: Borate glass dissolves to release ions promoting granulation/angiogenesis; inhibits colonization without antibiotics.
- Case Studies: Tendon-exposed DFU avoided amputation; osteomyelitis cavity filled/healed in 4 weeks.
- Advantages: Cost-effective, no refrigeration, versatile for contaminated wounds; supports non-compliant patients.
- Guests: AJ Ford (CEO, ETS); Dr. Marc Gitterle (wound expert).
Keywords: Mirragen, borate glass, DFU RCT, limb salvage, synthetic scaffold, Frank Aviles, Lizzie Hutton, AJ Ford, Marc Gitterle